BioNTech Seeks Shareholder Approval for Strategic Tax Restructuring

As BioNTech navigates a pivotal transition away from its pandemic-era revenue, the company is asking its shareholders to approve a novel corporate and tax structure. The move is designed to cushion significant financial losses during its expensive transformation into a focused oncology business.

Shareholder Vote to Authorize Financial Framework

A virtual Annual General Meeting scheduled for May 15, 2026, will see investors vote on a domination and profit transfer agreement with BioNTech’s wholly-owned subsidiary, BioNTech Discovery GmbH. The core objective is to establish a fiscal integration, or tax group. This structure would allow future profits generated by the subsidiary to be directly offset against losses at the parent company level. Following a reported net loss of €1.14 billion for the full 2025 fiscal year, this optimization is viewed as a logical step to preserve the firm’s substantial liquidity reserve, which stands at approximately €17.2 billion.

Management is also requesting enhanced financial flexibility. The proposal includes creating new authorized capital for 2026, which could amount to up to 50% of the current share capital. In a parallel governance change, the Supervisory Board is set to expand from six to eight members. The planned addition of two new specialists in oncology and clinical development highlights the strategic priority of these areas in the coming years.

Should investors sell immediately? Or is it worth buying BioNTech?

Operational Challenges and Pipeline Progress

The company’s operational environment remains challenging. For the current year, BioNTech anticipates a sharp revenue decline of around 25%, projecting sales between €2.0 billion and €2.3 billion. This forecast is impacted by the cessation of a U.S. government-mandated post-marketing study for its Covid-19 vaccine, conducted jointly with Pfizer. The study was halted not due to safety concerns, but because of insufficient participant enrollment during a mild infection season.

These headwinds underscore the critical importance of rapidly advancing its oncology pipeline. The company currently has nine Phase III trials underway, with six more slated to commence before the end of 2026. This would bring the total number of late-stage programs to fifteen by year-end.

Despite this progress, the leadership does not expect commercial revenue from its new cancer therapeutics to materialize in 2026. Consequently, the mid-May virtual meeting serves as a formal milestone where shareholders must endorse the financial and structural blueprint for a multi-year transitional phase.